Evidence map›Paper›PMID 34589395›Full record

ReviewActa pharmaceutica Sinica. B2021

Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.

Guoyi Tang, Sha Li, Cheng Zhang, Haiyong Chen, Ning Wang, Yibin Feng

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 8 pooled it
31.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 8 syntheses or guidelines pooled it, 337 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Efficacy and safety ofFrontiers in pharmacology · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. AI-Integrated Multi-Target Validation ofFoods (Basel, Switzerland) · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Podocyte Metabolic Reprogramming and Targeted Therapy.Journal of the American Society of Nephrology : JASN · 2026
    Review
  20. Review

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Guoyi TangSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
Sha LiSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
Cheng ZhangSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
Haiyong ChenSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
Ning WangSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
Yibin FengSchool of Chinese Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.

Indexed as

ACEI, angiotensin-converting enzyme inhibitorADE, adverse eventAGEs, advanced glycation end-productsAM, mesangial areaAMPKα, adenosine monophosphate-activated protein kinase αARB, angiotensin receptor blockerAREs, antioxidant response elementsATK, protein kinase BBAX, BCL-2-associated X proteinBCL-2, B-cell lymphoma 2BCL-XL, B-cell lymphoma-extra largeBMP-7, bone morphogenetic protein-7BUN, blood urea nitrogenBW, body weightcAMP, cyclic adenosine monophosphateC, control groupCCR, creatinine clearance rateCD2AP, CD2-associated proteinChinese medicineCHOP, C/EBP homologous proteinCI, confidence intervalCOL-I/IV, collagen I/IVCRP, C-reactive proteinCTGF, connective tissue growth factorDAG, diacylglycerolD, durationDG, glomerular diameterDiabetic kidney diseaseDiabetic nephropathyDKD, diabetic kidney diseaseDM, diabetes mellitusDN, diabetic nephropathyeGFR, estimated GFReIF2α, eukaryotic initiation factor 2αEMT, epithelial-to-mesenchymal transitionEP, E-prostanoid receptorER, endoplasmic reticulumESRD, end-stage renal diseaseET-1, endothelin-1ETAR, endothelium A receptorFBG, fasting blood glucoseFN, fibronectinGCK, glucokinaseGCLC, glutamate-cysteine ligase catalytic subunitGFR, glomerular filtration rateGLUT4, glucose transporter type 4GPX, glutathione peroxidaseGRB 10, growth factor receptor-bound protein 10GRP78, glucose-regulated protein 78GSK-3, glycogen synthase kinase 3Gαq, Gq protein alpha subunitHbA1c, glycosylated hemoglobinHDL-C, high density lipoprotein-cholesterolHerbal medicineHO-1, heme oxygenase-1ICAM-1, intercellular adhesion molecule-1IGF-1, insulin-like growth factor 1IGF-1R, insulin-like growth factor 1 receptorIKK-β, IκB kinase βIL-1β/6, interleukin 1β/6IRE-1α, inositol-requiring enzyme-1αIR, insulin receptorIRS, insulin receptor substrateIκB-α, inhibitory protein αJAK, Janus kinaseJNK, c-Jun N-terminal kinaseLC3, microtubule-associated protein light chain 3LDL-C, low density lipoprotein-cholesterolLDL, low-density lipoproteinLOX1, lectin-like oxidized LDL receptor 1MAPK, mitogen-activated protein kinaseMCP-1, monocyte chemotactic protein-1MDA, malondialdehydeMD, mean differenceMMP-2, matrix metallopeptidase 2Molecular targetmTOR, mammalian target of rapamycinMYD88, myeloid differentiation primary response 88N/A, not applicableNF-κB, nuclear factor kappa-light-chain-enhancer of activated B cellsN/O, not observedNOX-4, nicotinamide adenine dinucleotide phosphate-oxidase-4NQO1, NAD(P)H:quinone oxidoreductase 1NRF2, nuclear factor erythroid 2-related factor 2N/R, not reportedOCP, oxidative carbonyl proteinORP150, 150-kDa oxygen-regulated proteinp62, sequestosome 1 proteinP70S6K, 70-kDa ribosomal protein S6 kinasePAI-1, plasminogen activator inhibitor-1PARP, poly(ADP-Ribose) polymerasePBG, postprandial blood glucosePERK, protein kinase RNA-like eukaryotic initiation factor 2A kinasePGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1αPGE2, prostaglandin E2PI3K, phosphatidylinositol 3 kinasesPINK1, PTEN-induced putative kinase 1p-IRS1, phospho-IRS1PKC, protein kinase CPTEN, phosphatase and tensin homologRAGE, receptors of AGERASI, renin-angiotensin system inhibitorRCT, randomized clinical trialROS, reactive oxygen speciesSCr, serum creatinineSD-rat, Sprague–Dawley ratSD, standard deviationSignaling pathwaySIRT1, sirtuin 1SMAD, small mothers against decapentaplegicSMD, standard mean differenceSMURF-2, SMAD ubiquitination regulatory factor 2SOCS, suppressor of cytokine signaling proteinsSOD, superoxide dismutaseSTAT, signal transducers and activators of transcriptionSTZ, streptozotocinTBARS, thiobarbituric acid-reactive substanceTCM, traditional Chinese medicineTC, total cholesterolTFEB, transcription factor EBTGBM, thickness of glomerular basement membraneTGFβR-I/II, TGF-β receptor I/IITGF-β, tumor growth factor βTG, triglycerideTII, tubulointerstitial injury indexTLR-2/4, toll-like receptor 2/4TNF-α, tumor necrosis factor αTRAF5, tumor-necrosis factor receptor-associated factor 5T, treatment groupUACR, urinary albumin to creatinine ratioUAER, urinary albumin excretion rateUMA, urinary microalbuminUP, urinary proteinVCAM-1, vascular cell adhesion molecule-1VEGF, vascular endothelial growth factorWMD, weight mean differenceXBP-1, spliced X box-binding protein 1α-SMA, α smooth muscle actin

Identifiers

PMID34589395
PMCPMC8463270
OpenAlexW3127843453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.